These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28934761)

  • 41. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
    Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
    World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current status on response to treatment in locally advanced rectal cancer: what the radiologist should know.
    Granata V; Grassi R; Fusco R; Izzo F; Brunese L; Delrio P; Avallone A; Pecori B; Petrillo A
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12050-12062. PubMed ID: 33336723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The potential predictive value of MRI and PET-CT in mucinous and nonmucinous rectal cancer to identify patients at high risk of metastatic disease.
    Barbaro B; Leccisotti L; Vecchio FM; Di Matteo M; Serra T; Salsano M; Poscia A; Coco C; Persiani R; Alfieri S; Gambacorta MA; Valentini V; Giordano A; Bonomo L
    Br J Radiol; 2017 Jan; 90(1069):20150836. PubMed ID: 27845566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Ryan R; Gibbons D; Hyland JM; Treanor D; White A; Mulcahy HE; O'Donoghue DP; Moriarty M; Fennelly D; Sheahan K
    Histopathology; 2005 Aug; 47(2):141-6. PubMed ID: 16045774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extramural depth of rectal cancer tumor invasion at thin-section MRI: predicting treatment response to neoadjuvant chemoradiation.
    Tong T; Sun Y; Cai S; Zhang Z; Gu Y
    Oncotarget; 2015 Oct; 6(30):30277-86. PubMed ID: 26309163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy?
    Park SY; Chang HJ; Kim DY; Jung KH; Kim SY; Park JW; Oh JH; Lim SB; Choi HS; Jeong SY
    Histopathology; 2011 Oct; 59(4):650-9. PubMed ID: 22014046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endoscopy and magnetic resonance imaging-based prediction of ypT stage in patients with rectal cancer who received chemoradiotherapy: Results from a prospective study of 110 patients.
    Cho MS; Kim H; Han YD; Hur H; Min BS; Baik SH; Cheon JH; Lim JS; Lee KY; Kim NK
    Medicine (Baltimore); 2019 Aug; 98(35):e16614. PubMed ID: 31464897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MRI predictive factors for long-term outcomes of low rectal tumours.
    Shihab OC; Taylor F; Salerno G; Heald RJ; Quirke P; Moran BJ; Brown G
    Ann Surg Oncol; 2011 Nov; 18(12):3278-84. PubMed ID: 21590453
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy.
    Bhoday J; Smith F; Siddiqui MR; Balyasnikova S; Swift RI; Perez R; Habr-Gama A; Brown G
    Dis Colon Rectum; 2016 Oct; 59(10):925-33. PubMed ID: 27602923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer.
    Lee SY; Kim CH; Kim YJ; Kim HR
    Oncology; 2015; 89(6):311-8. PubMed ID: 26426305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
    Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diffusion and Perfusion Imaging in Rectal Cancer Restaging.
    Granata V; Fusco R; Setola SV; Cozzi D; Rega D; Petrillo A
    Semin Ultrasound CT MR; 2023 Jun; 44(3):117-125. PubMed ID: 37245878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of an Objective MRI-Based Tumor Regression Grade (mrTRG) Score and a Subjective Likert Score for Assessing Treatment Response in Locally Advanced Rectal Cancers-A Retrospective Study.
    Katdare AN; Baheti AD; Pangarkar SY; Mistry KA; Ankathi SK; Haria PD; Choudhari AJ; Guha A; Gala K; Shetty N; Kulkarni S; Ramadwar M; Bal M
    Indian J Radiol Imaging; 2024 Jan; 34(1):69-75. PubMed ID: 38106857
    [No Abstract]   [Full Text] [Related]  

  • 57. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative MRI accuracy after neoadjuvant chemoradiation for locally advanced rectal cancer.
    Popiţa AR; Rusu A; Muntean V; Cadariu PA; Irimie A; Lisencu C; Pop B; Resiga L; Fekete Z; Badea R
    Med Pharm Rep; 2023 Jul; 96(3):258-268. PubMed ID: 37577010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rectal Signet Ring Cell Carcinoma: Post-Chemoradiotherapy Evaluation by MRI and Corresponding to Pathology.
    Zhou Y; Li Q; Mao Y
    Front Surg; 2022; 9():841645. PubMed ID: 35310426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment.
    Trakarnsanga A; Gönen M; Shia J; Nash GM; Temple LK; Guillem JG; Paty PB; Goodman KA; Wu A; Gollub M; Segal N; Saltz L; Garcia-Aguilar J; Weiser MR
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25249540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.